Melissa Paddock is an associate in the firm’s Technology & Life Sciences group.

Ms. Paddock represents biotechnology, pharmaceutical, diagnostic and medical device companies in connection with their intellectual property, M&A and commercial transactions. Ms. Paddock advises clients on development and commercialization collaborations, licensing, manufacturing, supply, clinical trial and services agreements. Ms. Paddock also has experience structuring and negotiating brand and generic settlement and license agreements related to ANDA litigation. Ms. Paddock rejoined Goodwin in 2015.

Previously, as Senior Counsel in the IP Litigation Group at Goodwin, Ms. Paddock focused her practice on intellectual property litigation, with a particular emphasis on pharmaceutical patent litigation under the Hatch-Waxman Act.





Ms. Paddock’s representative transactions include:

  • Teva Pharmaceuticals, in its sale of its specialty global women’s health business for a combined value of $2.5 billion, including sale of Paragard®  business to CooperSurgical for $1.1 billion, ex-U.S. women’s health business to CVC Capital Partners for $703 million, and Plan B One-Step® franchise to Foundation Consumer Healthcare for $675 million
  • bluebird bio in connection with its $1 billion collaboration with Medigene to develop T cell receptor-based immunotherapies
  • Ampersand Capital Partners and 1315 Capital in their acquisition of Genoptix, Inc., a provider of comprehensive testing solutions in hematology and solid tumor molecular profiling, from Novartis Pharmaceuticals Corporation
  • Brammer Bio in its acquisition of a biologics manufacturing facility from Biogen
  • Teva Pharmaceuticals, in its $40.5 billion acquisition of Allergan’s (fka Actavis/Watson) Global Generic Pharmaceuticals Business
  • Hikma Pharmaceuticals, in its sale of certain generic pharmaceutical products to Renaissance Pharma
  • Lupin, in connection with exclusive collaboration and license agreement with Monosol regarding development and commercialization of innovative drug products and new platform technologies
  • Teva Pharmaceuticals, in connection with patent license and settlement agreements related to settlements of various brand and generic pharmaceutical patent litigation matters
  • Fresenius Kabi, in connection with patent license and settlement agreements related to settlements of various pharmaceutical patent litigation matters
  • Licensing of intellectual property assets from research institutions
Professional Experience

Ms. Paddock is a member of the Boston Bar Association and the Women’s Bar Association.

Prior to joining Goodwin, Ms. Paddock was an associate at Kenyon & Kenyon, where her practice concentrated on patent litigation and counseling in the pharmaceutical, medical device, and biotechnology fields.

While in law school, Ms. Paddock was named a Paul J. Liacos and Edward F. Hennessey Scholar and was a member of the American Journal of Law & Medicine.

Prior to law school, Ms. Paddock worked for four years as a chemical engineer for Hoffmann-LaRoche, where she managed projects involving the transfer and scale up of technology for the manufacture of pharmaceuticals and fine chemicals from research and development facilities in Switzerland to production sites in the United States.

In The News









J.D., 1999
Boston University

(cum laude)

B.S., 1992
Worcester Polytechnic Institute

(with High Distinction)



New York
U.S. Patent and Trademark Office (USPTO)


U.S. District Court for the District of Massachusetts
U.S. District Court for the Southern District of New York
U.S. District Court for the Eastern District of New York
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique